Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisaku Masuda

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Journal of Atherosclerosis and Thrombosis|November 11, 2016
Postprandial Hyperlipidemia and Remnant LipoproteinsDaisaku Masuda, Shizuya Yamashita
Current Atherosclerosis Reports|January 25, 2020
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic DiseasesShizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa
Current Opinion in Lipidology|July 1, 2015
Did we abandon probucol too soon?Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa
Journal of Atherosclerosis and Thrombosis|April 2, 2019
Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic DiseasesShizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa
Atherosclerosis|December 7, 2019
Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized studyDaisaku Masuda, Yuko Miyata, Shingo Matsui, et al.
Cardiovascular Diabetology|November 28, 2020
Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary reportChie Iitake, Daisaku Masuda, Masahiro Koseki, et al.
Journal of Atherosclerosis and Thrombosis|May 22, 2018
Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician AttitudesShizuya Yamashita, Daisaku Masuda, Hidenori Arai, et al.
Metabolites|May 26, 2023
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and AtherosclerosisShizuya Yamashita, Manfredi Rizzo, Ta-Chen Su, et al.
Physiological Reports|May 21, 2017
CD36 is essential for endurance improvement, changes in whole-body metabolism, and efficient PPAR-related transcriptional responses in the muscle with exercise trainingMark Christian C Manio, Shigenobu Matsumura, Daisaku Masuda, et al.
American Journal of Ophthalmology Case Reports|April 25, 2018
Clinical features and visual function in a patient with Fish-eye disease: Quantitative measurements and optical coherence tomographyMasanori Kanai, Shizuka Koh, Daisaku Masuda, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Journal of Atherosclerosis and Thrombosis|November 11, 2016
Postprandial Hyperlipidemia and Remnant LipoproteinsDaisaku Masuda, Shizuya Yamashita
Current Atherosclerosis Reports|January 25, 2020
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic DiseasesShizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa
Current Opinion in Lipidology|July 1, 2015
Did we abandon probucol too soon?Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa
Journal of Atherosclerosis and Thrombosis|April 2, 2019
Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic DiseasesShizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa
Atherosclerosis|December 7, 2019
Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized studyDaisaku Masuda, Yuko Miyata, Shingo Matsui, et al.
Cardiovascular Diabetology|November 28, 2020
Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary reportChie Iitake, Daisaku Masuda, Masahiro Koseki, et al.
Journal of Atherosclerosis and Thrombosis|May 22, 2018
Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician AttitudesShizuya Yamashita, Daisaku Masuda, Hidenori Arai, et al.
Metabolites|May 26, 2023
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and AtherosclerosisShizuya Yamashita, Manfredi Rizzo, Ta-Chen Su, et al.
Physiological Reports|May 21, 2017
CD36 is essential for endurance improvement, changes in whole-body metabolism, and efficient PPAR-related transcriptional responses in the muscle with exercise trainingMark Christian C Manio, Shigenobu Matsumura, Daisaku Masuda, et al.
American Journal of Ophthalmology Case Reports|April 25, 2018
Clinical features and visual function in a patient with Fish-eye disease: Quantitative measurements and optical coherence tomographyMasanori Kanai, Shizuka Koh, Daisaku Masuda, et al.
Pageof 9